Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393937 · ClinicalTrials.gov registry record · Phase 3
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
A Phase 3 study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea, sponsored by bioRASI.
- Completed
- Registry status
- Phase 3
- Development phase
- 963
- Enrollment target
- 20
- Study locations
NCT02393937 is a Phase 3 study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea that has completed, run by bioRASI. The registered enrollment target is 963 participants, above the 192-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (402% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT02393937, a Phase 3 study of Papulopustular Rosacea and Erythematotelangiectatic Rosacea, has completed, sponsored by bioRASI.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 963 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.
Conditions Studied
Interventions
- DRUG Reference: Metronidazole Gel 1%
- DRUG Test: Metronidazole Gel 1%
- DRUG Placebo Gel
Study Locations (20)
Florida
- - Boca Raton
- - Clearwater
- - Miami
- - Miami
- - Miramar
- - Ocala
- - Tampa
California
- - Los Angeles
- - San Diego
North Carolina
- - High Point
- - Raleigh
Kentucky
- - Lexington
Massachusetts
- - Watertown
Nevada
- - Las Vegas
New York
- - New York
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 963 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393937
The ClinicalTrials.gov registry entry for NCT02393937 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 963 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (402% higher). The listed sponsor is bioRASI, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Papulopustular Rosacea appearing as the primary indexed condition, and to 3 interventions - of which Reference: Metronidazole Gel 1% is the first listed.
NCT02393937 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02393937 about?
NCT02393937 is a clinical study titled "A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea". The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.
What is the current status of trial NCT02393937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 963 participants. The study started on 2015-02. Estimated completion is 2015-10.
What conditions does trial NCT02393937 study?
This clinical trial studies the following conditions: Papulopustular Rosacea, Erythematotelangiectatic Rosacea.
What interventions are being tested in trial NCT02393937?
The interventions under investigation include: Reference: Metronidazole Gel 1% (DRUG), Test: Metronidazole Gel 1% (DRUG), Placebo Gel (DRUG).
Who is sponsoring clinical trial NCT02393937?
This trial is sponsored by bioRASI, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393937 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
COMPLETED · Phase 3
-
Phase 3 Papulopustular Rosacea Study
COMPLETED · Phase 3
-
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
COMPLETED · Phase 3
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.